IOVANCE BIOTHERAPEUTICS, INC.IOVAEarnings & Financial Report

Nasdaq · pharmaceutical industry

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

NextMar 13, 2026

Revenue

$67.5M

Gross Profit

$29.0M

Operating Profit

$-94.9M

Net Profit

$-91.3M

Gross Margin

43.0%

Operating Margin

-140.7%

Net Margin

-135.3%

YoY Growth

15.2%

EPS

$-0.25

Financial Flow

IOVANCE BIOTHERAPEUTICS, INC. Q3 2025 Financial Summary

IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $67.5M for Q3 2025, with a net profit of $-91.3M (-135.3% margin). Cost of goods sold was $38.5M, operating expenses totaled $123.9M.

Key Financial Metrics

Total Revenue	$67.5M
Net Profit	$-91.3M
Gross Margin	43.0%
Operating Margin	-140.7%
Report Period	Q3 2025

IOVANCE BIOTHERAPEUTICS, INC. Annual Revenue by Year

IOVANCE BIOTHERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $164.1M).

Year	Annual Revenue
2024	$164.1M
2023	$1.2M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$482000	$715000	$31.1M	$58.6M	$73.7M	$49.3M	$60.0M	$67.5M
YoY Growth	N/A	N/A	12969.7%	12385.1%	15189.2%	6798.5%	92.7%	15.2%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$780.4M	$869.8M	$964.3M	$991.1M	$910.4M	$966.7M	$907.4M	$904.9M
Liabilities	$195.7M	$189.8M	$195.8M	$217.7M	$200.0M	$198.9M	$208.9M	$202.7M
Equity	$584.6M	$680.0M	$768.5M	$773.5M	$710.4M	$767.9M	$698.5M	$702.3M